Amgen Expands U.S. Manufacturing Network with $300M Investment

Amgen announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.

"Amgen has been a leader in U.S. biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing," said Robert A. Bradway, chairman and chief executive officer at Amgen. "By growing our operations in Puerto Rico, we are ensuring patients have access to the medicines they need, investing in the long-term strength of our domestic supply chain and supporting American jobs."

"This investment confirms that the policies we have implemented are working. Puerto Rico has more than 60 years of excellence in the biopharmaceutical sector, supported by a highly skilled workforce and world‑class infrastructure, and Amgen knows this better than anyone," said Puerto Rico Governor Jenniffer González Colón. "We will continue working to make Puerto Rico the number one destination for advanced manufacturing in the United States."

"Amgen's additional $300 million commitment in Juncos is a powerful signal that the future of American biomanufacturing is being built here. Combined with the $650 million previously announced, this represents nearly $1 billion in confidence in our workforce, our capabilities and our ability to produce life‑saving medicines," said Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce. "This is the result of our commitment to building a pro‑business jurisdiction where world‑class companies like Amgen can grow, invest and thrive."